Literature DB >> 1899814

Mycoplasma pneumoniae infections and Stevens-Johnson syndrome. Report of eight cases and review of the literature.

M Levy1, N H Shear.   

Abstract

On the basis of a literature review and eight cases of our own, we analyzed 37 cases of Mycoplasma pneumoniae (MP) infection and Stevens-Johnson syndrome (SJS). Our clinical and laboratory findings do not differ from those reported in the literature for MP infection with no exanthem or for SJS of various etiologies. Eighty percent of the children presented with symptoms of upper respiratory tract infection (URTI) (cough, fever, sore throat, malaise, headache), with a mean of 10 days (range 1 to 30) before skin rash broke out. Skin manifestations occurred in 94.2% of the patients after 3 to 21 days (mean 10.3 days) of fever. The exanthem, composed predominantly of maculopapular and vesicular, was distributed chiefly on the trunk and extremities and lasted less than 14 days in 87.8% of the patients. Stomatitis was observed in 91.6% of the patients and conjunctivitis in 50%. No consistent pattern seems to emerge by which one could predict the existence of MP infection causing SJS. The complications of SJS associated with MP seem less frequent (2.7%) and much less severe than in cases where SJS arises from other reported causes. Because coincidence cannot be excluded from the assessments of the degree and rate of improvement for the few patients treated with corticosteroid, from the low frequency of complications, and from the mortality rate of zero in this series of patients, the use of corticosteroids for SJS associated with MP infection is questionable.

Entities:  

Mesh:

Year:  1991        PMID: 1899814     DOI: 10.1177/000992289103000107

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  8 in total

1.  Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations.

Authors:  Christos S Zipitis; Nandu Thalange
Journal:  Eur J Pediatr       Date:  2006-09-29       Impact factor: 3.183

2.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

3.  Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic.

Authors:  David A Wetter; Michael J Camilleri
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

4.  Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience.

Authors:  Rachel Forman; Gideon Koren; Neil H Shear
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Evaluation of four commercial immunoglobulin G (IgG)- and IgM-specific enzyme immunoassays for diagnosis of Mycoplasma pneumoniae infections.

Authors:  J Petitjean; A Vabret; S Gouarin; F Freymuth
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

Review 6.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome.

Authors:  Daniel Olson; Louise K Francois Watkins; Alicia Demirjian; Xia Lin; Christine C Robinson; Kristin Pretty; Alvaro J Benitez; Jonas M Winchell; Maureen H Diaz; Lisa A Miller; Teresa A Foo; Melanie D Mason; Ursula L Lauper; Oren Kupfer; Jeffrey Kennedy; Mary P Glodé; Preeta K Kutty; Samuel R Dominguez
Journal:  Pediatrics       Date:  2015-08       Impact factor: 7.124

8.  Concomitance or consequence? Stevens-Johnson syndrome in COVID-19: A case report.

Authors:  Carmen Manciuc; Georgiana Alexandra Lacatusu; Andrei Vata; Cristina Sapaniuc; Carmen Mihaela Arteni; Florin Dumitru Petrariu
Journal:  Exp Ther Med       Date:  2022-02-02       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.